Literature DB >> 26141599

Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.

Li Zeng1, Bo Wang1, Sean A Merillat1, Eiko N Minakawa2, Matthew D Perkins3, Biswarathan Ramani1, Sara J Tallaksen-Greene1, Maria do Carmo Costa1, Roger L Albin4, Henry L Paulson5.   

Abstract

Accumulation of mutant polyglutamine proteins in intraneuronal inclusions is a hallmark of polyglutamine diseases. Impairment of protein clearance systems and sequestration of clearance-related proteins into inclusions occur in many protein folding diseases, including polyglutamine diseases. The ubiquitin-binding and proteasome adaptor protein UBQLN2 participates in protein homeostasis and localizes to inclusions in various neurodegenerative diseases. Employing mouse models and human brain tissue of Huntington's disease (HD) and spinocerebellar ataxia type 3 (SCA3), we show that UBQLN2 is selectively recruited to inclusions in HD but not SCA3. Consistent with this result, in a cell-based system mutant HTT interacts with UBQLN2 through the UBA domain while the SCA3 disease protein ATXN3, a deubiquitinating enzyme, does not interact with UBQLN2. Differential recruitment of UBQLN2 to aggregates in HD and SCA3 underscores the heterogeneity of inclusions in polyglutamine diseases and suggests that components of neuronal protein quality control may be differentially perturbed in distinct polyQ diseases.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Huntington's disease; Polyglutamine; SCA3; UBA; UBL; UBQLN2

Mesh:

Substances:

Year:  2015        PMID: 26141599      PMCID: PMC4642276          DOI: 10.1016/j.nbd.2015.06.017

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

1.  Ubiquitin-related proteins regulate interaction of vimentin intermediate filaments with the plasma membrane.

Authors:  A L Wu; J Wang; A Zheleznyak; E J Brown
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.

Authors:  H L Paulson; M K Perez; Y Trottier; J Q Trojanowski; S H Subramony; S S Das; P Vig; J L Mandel; K H Fischbeck; R N Pittman
Journal:  Neuron       Date:  1997-08       Impact factor: 17.173

3.  The UBL domain of PLIC-1 regulates aggresome formation.

Authors:  Renu Heir; Celine Ablasou; Emilie Dumontier; Meghan Elliott; Christine Fagotto-Kaufmann; Fiona K Bedford
Journal:  EMBO Rep       Date:  2006-11-03       Impact factor: 8.807

4.  YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.

Authors:  Cemal K Cemal; Christopher J Carroll; Lorraine Lawrence; Margaret B Lowrie; Piers Ruddle; Sahar Al-Mahdawi; Rosalind H M King; Mark A Pook; Clare Huxley; Susan Chamberlain
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

5.  Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains.

Authors:  Han Seok Ko; Takashi Uehara; Kazuhiro Tsuruma; Yasuyuki Nomura
Journal:  FEBS Lett       Date:  2004-05-21       Impact factor: 4.124

6.  Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates.

Authors:  Hiroshi Doi; Kenichi Mitsui; Masaru Kurosawa; Yoko Machida; Yoshiyuki Kuroiwa; Nobuyuki Nukina
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

7.  Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis.

Authors:  Yaohui Chai; Jianqiang Shao; Victor M Miller; Aislinn Williams; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

8.  Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.

Authors:  Hongmin Wang; Precious J Lim; Chaobo Yin; Matthias Rieckher; Bruce E Vogel; Mervyn J Monteiro
Journal:  Hum Mol Genet       Date:  2006-02-06       Impact factor: 6.150

Review 9.  The roles of intracellular protein-degradation pathways in neurodegeneration.

Authors:  David C Rubinsztein
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

10.  Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin.

Authors:  Hui Yang; Xiaoyan Zhong; Petek Ballar; Shouqing Luo; Yuxian Shen; David C Rubinsztein; Mervyn J Monteiro; Shengyun Fang
Journal:  Exp Cell Res       Date:  2006-11-03       Impact factor: 3.905

View more
  10 in total

1.  Ubiquilin-2 differentially regulates polyglutamine disease proteins.

Authors:  Julia E Gerson; Nathaniel Safren; Svetlana Fischer; Ronak Patel; Emily V Crowley; Jacqueline P Welday; Alexandra K Windle; Sami Barmada; Henry L Paulson; Lisa M Sharkey
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

2.  Profilin reduces aggregation and phase separation of huntingtin N-terminal fragments by preferentially binding to soluble monomers and oligomers.

Authors:  Ammon E Posey; Kiersten M Ruff; Tyler S Harmon; Scott L Crick; Aimin Li; Marc I Diamond; Rohit V Pappu
Journal:  J Biol Chem       Date:  2018-01-22       Impact factor: 5.157

3.  RTL8 promotes nuclear localization of UBQLN2 to subnuclear compartments associated with protein quality control.

Authors:  Harihar Milaganur Mohan; Hanna Trzeciakiewicz; Amit Pithadia; Emily V Crowley; Regina Pacitto; Nathaniel Safren; Bryce Trotter; Chengxin Zhang; Xiaogen Zhou; Yang Zhang; Venkatesha Basrur; Henry L Paulson; Lisa M Sharkey
Journal:  Cell Mol Life Sci       Date:  2022-03-05       Impact factor: 9.207

4.  Disrupting the Balance of Protein Quality Control Protein UBQLN2 Accelerates Tau Proteinopathy.

Authors:  Julia E Gerson; Stephanie Sandoval-Pistorius; Jacqueline P Welday; Aleija Rodriguez; Jordan D Gregory; Nyjerus Liggans; Kylie Schache; Xingli Li; Hanna Trzeciakiewicz; Sami Barmada; Lisa M Sharkey; Henry L Paulson
Journal:  J Neurosci       Date:  2022-01-26       Impact factor: 6.709

5.  Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.

Authors:  Vicky Hakim-Eshed; Ayub Boulos; Chen Cohen-Rosenzweig; Libo Yu-Taeger; Tamar Ziv; Yong Tae Kwon; Olaf Riess; Hoa Huu Phuc Nguyen; Noam E Ziv; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-16       Impact factor: 11.205

6.  Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly.

Authors:  Lisa M Sharkey; Nathaniel Safren; Amit S Pithadia; Julia E Gerson; Mark Dulchavsky; Svetlana Fischer; Ronak Patel; Gabrielle Lantis; Naila Ashraf; John H Kim; Alia Meliki; Eiko N Minakawa; Sami J Barmada; Magdalena I Ivanova; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-17       Impact factor: 11.205

7.  The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.

Authors:  Bo Wang; Li Zeng; Sean A Merillat; Svetlana Fischer; Joseph Ochaba; Leslie M Thompson; Sami J Barmada; Kenneth M Scaglione; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2017-10-03       Impact factor: 5.996

8.  Shared and divergent phase separation and aggregation properties of brain-expressed ubiquilins.

Authors:  Julia E Gerson; Hunter Linton; Jiazheng Xing; Alexandra B Sutter; Fayth S Kakos; Jaimie Ryou; Nyjerus Liggans; Lisa M Sharkey; Nathaniel Safren; Henry L Paulson; Magdalena I Ivanova
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.996

9.  Carboxyl Terminus of Hsp70-Interacting Protein Is Increased in Serum and Cerebrospinal Fluid of Patients With Spinocerebellar Ataxia Type 3.

Authors:  Zheng-Wei Hu; Zhi-Hua Yang; Shuo Zhang; Yu-Tao Liu; Jing Yang; Yan-Lin Wang; Cheng-Yuan Mao; Qi-Meng Zhang; Chang-He Shi; Yu-Ming Xu
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

10.  DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases.

Authors:  Nan Zhang; Brittani Bewick; Jason Schultz; Anjana Tiwari; Robert Krencik; Aijun Zhang; Kaho Adachi; Guangbin Xia; Kyuson Yun; Partha Sarkar; Tetsuo Ashizawa
Journal:  Neurotherapeutics       Date:  2021-06-23       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.